BHWM
ACAD icon

Bay Harbor Wealth Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Bay Harbor Wealth Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$200 Buy
9
+2
+29% +$48 ﹤0.01% 1152
2025
Q4 		$186 Buy
7
+3
+75% +$72 ﹤0.01% 1128
2025
Q3 		$85 Buy
+4
New +$95 ﹤0.01% 1192

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Bay Harbor Wealth Management's ACAD Position: Q1 2026 in Review

Bay Harbor Wealth Management increased its Acadia Pharmaceuticals (ACAD) stake by 29% in Q1 2026, buying an estimated $48 and bringing the position to 9 shares worth $200. The position accounts for ﹤0.01% of the portfolio, ranked #1152.

Bay Harbor Wealth Management first reported a position in ACAD in Q3 2025 and has held it in 3 quarters since. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Bay Harbor Wealth Management held 9 shares of Acadia Pharmaceuticals worth $200 as of Q1 2026.
  • Bay Harbor Wealth Management bought 2 Acadia Pharmaceuticals shares in Q1 2026, an estimated $48.
  • Acadia Pharmaceuticals made up ﹤0.01% of Bay Harbor Wealth Management's portfolio in Q1 2026, its #1152 holding.
  • Bay Harbor Wealth Management first reported a position in Acadia Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Bay Harbor Wealth Management's 13F filing for Q1 2026, filed 14 Apr 2026.